This is a significative milestone, which well illustrates the hype and dynamic EU Biotechs are experiencing right now…

The data was published in a report from our neighbours (and friendly competitors) Berlin-based BIOCOM AG. The full report contains lot of data, but here’s a highlight of few interesting figures:

preview_biocom_report_european_biotech

  • The 191 EU-listed Biotech companies raised €6.26Bn in 2015, twice as high as in 2014 (€3.44Bn)
  • Paris and London have as many Biotech listed on their stock exchanges: 38 each
  • 25 European Biotech companies trade on the NASDAQ
  • Top 3 IPOs in 2015: Adaptimmune (€170M) on NASDAQ, Cassiopedia (€168M) in Zurich, and Biocartis (€115M) in Brussels…
  • €5.05Bn was poured into the companies via follow-on financings, that’s 130% more than last year

For the Data addicts, you should definitely consider having a look at the reports which contain more on these figures, as well as exclusive interviews and trends predictions….Click here to find out more.

Philip Hemme

Philip Hemme

Young French-German Entrepreneur, Co-Founder & CEO of Labiotech.eu. High-level table-tennis player & German beer lover.

Previous post

Swiss Biotech Merger: Bones + Oncology + Vaccines?

Next post

Fighting Lupus with an Autoimmune Disease Vaccine that Uses Limpet Proteins

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *